1. Home
  2. SCD vs ALT Comparison

SCD vs ALT Comparison

Compare SCD & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LMP Capital and Income Fund Inc.

SCD

LMP Capital and Income Fund Inc.

HOLD

Current Price

$15.46

Market Cap

359.2M

Sector

Finance

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.78

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCD
ALT
Founded
2003
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
359.2M
421.5M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
SCD
ALT
Price
$15.46
$2.78
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.67
AVG Volume (30 Days)
94.2K
3.9M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
9.63%
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$13.79
$2.56
52 Week High
$16.18
$6.44

Technical Indicators

Market Signals
Indicator
SCD
ALT
Relative Strength Index (RSI) 49.03 41.51
Support Level $15.13 $2.72
Resistance Level $15.48 $3.09
Average True Range (ATR) 0.18 0.13
MACD -0.01 -0.03
Stochastic Oscillator 52.83 6.27

Price Performance

Historical Comparison
SCD
ALT

About SCD LMP Capital and Income Fund Inc.

Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: